3-benzyloxy-naphthalene-2-carboxylic acid, benzyl ester | 203807-48-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-benzyloxy-naphthalene-2-carboxylic acid, benzyl ester
• 英文别名: benzyl 3-(benzyloxy)naphthalene-2-carboxylate；Benzyl 3-(benzyloxy)naphthalene-2-carboxylate；benzyl 3-phenylmethoxynaphthalene-2-carboxylate
• CAS: 203807-48-1
• 化学式: C₂₅H₂₀O₃
• 分子量: 368.432
• InChiKey: UPHFPDHKXDSDBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-naphthalene-2-carboxylic acid, benzyl ester 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 sodium 3-(benzyloxy)naphthalene-2-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES
  [FR] INHIBITEURS DE RÉPLICATION VIRALE, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  本发明涉及化合物，及其在治疗或预防病毒性疾病，包括HIV方面的应用。

  公开号：

  WO2012140243A1
• 作为产物：
  描述：

  溴甲苯 、 2-羟基-3-萘甲酸 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.5h， 生成 3-benzyloxy-naphthalene-2-carboxylic acid, benzyl ester
  参考文献：
  名称：

  铜催化好氧氧化交叉偶联对映体合成3,3'-双取代的2-氨基-2'-羟基-1,1'-联萘

  摘要：

  首次成功开发了具有挑战性的2-萘胺和2-萘酚的直接不对称催化好氧氧化交叉偶联，使用新型Cu I / SPDO系统。获得了对映体富集的3,3'-双取代NOBIN，可以很容易地衍生出不同的手性配体和催化剂。该反应具有高对映选择性（高达96％ee）和良好的产率（高达80％）。在DFT计算表明，CF之间在F-H相互作用3的L17和2-萘酚的H-1,8，和两个联接伙伴之间的π-π堆叠可以在这个交叉偶联反应的enantiocontrol起到至关重要的作用。

  DOI：

  10.1002/anie.202015001

文献信息

• INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES
  申请人：Chasset Sophie

  公开号：US20140031338A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

  本发明涉及化合物及其在治疗或预防病毒性疾病，包括HIV方面的应用。
• Synthesis of key sandramycin analogs: systematic examination of the intercalation chromophore
  作者：Dale L. Boger、Jyun-Hung Chen、Kurt W. Saionz、Qing Jin

  DOI：10.1016/s0968-0896(97)10014-1

  日期：1998.1

  The preparation and examination of 2-22 constituting a systematic study of the chromophore of sandramycin (1) are detailed. Fluorescence quenching studies were used to establish binding constants for 1-24 within calf thymus DNA, within a single high affinity bis-intercalation binding site 5'-d(GCATGC)(2), and to establish the preference for sandramycin binding to 5'-d(GCXXGC)(2) where XX = AT, TA, GC, and CG. From the latter studies, sandramycin was found to exhibit a preference that follows the order: 5'-d(GCATGC)(2) > 5'-d(GCGCGC)(2), Delta Delta G degrees = 0.3 kcal/mol > 5'-d(GCTAGC)(2), 5'-d(GCCGGC)(2), Delta Delta G degrees = 0.6 kcal/mol although it binds with high affinity to all four deoxyoligonucleotides. The two highest affinity sequences constitute repeating 5'-PuPy motifs with each intercalation event occurring at a 5'-PyPu step. The most effective sequence constitutes the less stable duplex, contains the sterically most accessible minor groove central to the bis-intercalation site, and the ability to accept two gly-NH/T C2 carbonyl H-bonds identified in prior NMR studies. Similarly, the contribution of the individual structural features of the chromophore were assessed with the high affinity duplex sequence 5'-d(GCATGC)(2). To a first approximation, the cytotoxic properties were found to parallel trends established in the DNA binding affinities. The exception to this generalization was 4 which lacks the sandramycin chromophore phenol. Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of IpM-10 nM placing it among the most potent agents identified to date. Additionally, the first disclosure of the HIV-1 reverse transcriptase inhibitory activity of sandramycin (1) as well as that of its key analogs are described and define the chromophore structural features required for their exceptional potency. Two analogs, 18 and 3, roughly maintain the HIV-I reverse transcriptase inhibitory potency of 1 but exhibit substantially diminished cytotoxic activity (10(2) - 10(3)x). (C) 1998 Elsevier Science Ltd. All rights reserved.
• US9604900B2
  申请人：——

  公开号：US9604900B2

  公开（公告）日：2017-03-28